Pdt Partners, LLC Adverum Biotechnologies, Inc. Transaction History

Pdt Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.08 - $3.6 $83,855 - $145,134	-40,315 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $6,384 - $20,064	-1,900 Reduced 4.5%	40,315 $141,000
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $29,798 - $46,210	-3,218 Reduced 7.08%	42,215 $416,000
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $447,060 - $647,874	45,433 New	45,433 $492,000
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $1.1 Million - $2.26 Million	-138,200 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $707,584 - $1.69 Million	138,200 New	138,200 $1.59 Million
Q4 2018 Feb 14, 2019	SELL	$2.87 - $5.92 $449,155 - $926,480	-156,500 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$4.5 - $7.6 $238,941 - $403,544	-53,098 Reduced 25.33%	156,500 $947,000
Q2 2018 Aug 14, 2018	SELL	$5.3 - $6.9 $933,340 - $1.22 Million	-176,102 Reduced 45.66%	209,598 $1.11 Million
Q1 2018 May 15, 2018	BUY	$3.65 - $7.95 $1.41 Million - $3.07 Million	385,700 New	385,700 $2.24 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.